FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北海康成製藥有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01228 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | 0.00001 | USD | | 50,000 | 本月底法定/註冊 ...

Group 1 - As of February 4, 100 stocks reached a 52-week high, with METROPOLIS CAP (08621), Asia Backup (08290), and Wenling Tooling (01379) leading the high rate at 74.55%, 63.89%, and 57.48% respectively [1] - METROPOLIS CAP closed at 0.048 with a peak of 0.096, while Asia Backup closed at 0.032 with a peak of 0.059, and Wenling Tooling closed at 3.400 with a peak of 6.000 [1] - Other notable stocks that reached new highs include Asia Internet Technology (00679) at 46.23% and Asia Pacific Financial Investment (08193) at 25.45% [1] Group 2 - The 52-week low rankings show that Gaodi Co. (01676) had the largest decline at -45.71%, followed by Xixiang Group (02473) at -23.42% and Jianfa Xingsheng (00731) at -21.51% [3] - Gaodi Co. closed at 0.243 with a low of 0.171, while Xixiang Group closed at 2.370 with a low of 2.060, and Jianfa Xingsheng closed at 0.137 with a low of 0.135 [3] - Other significant declines include Huaxia SOL-R (83460) at -14.34% and Huaxia SOL-U (09460) at -13.97% [3]

Core Insights - The Chinese pharmaceutical industry is set to benefit from a significant policy update with the revised Drug Administration Law Implementation Regulations, which will take effect on May 15, 2026, marking the first comprehensive revision in 23 years [1][2] Group 1: Policy Changes - The revised regulations include over 90% changes from the previous version, emphasizing support for drug innovation and clinical value-oriented research [1] - New measures include a market exclusivity period for pediatric drugs and rare disease medications, with up to 2 years for pediatric drugs and up to 7 years for rare disease treatments, encouraging investment in these areas [1][2] Group 2: Industry Impact - The introduction of a market exclusivity period is expected to incentivize more pharmaceutical companies to invest in the rare disease sector, potentially leading to a reduction in industry competition [2] - The regulations also establish a fast-track review process for drug approvals, aiming to expedite the availability of new and effective treatments for patients [2][3] Group 3: Concerns and Future Outlook - Industry experts express the need for clearer implementation details regarding the applicability of the new exclusivity policies to drugs already approved before the regulations take effect [4] - The overall sentiment is optimistic, with expectations that the revised regulations will significantly enhance the innovation landscape in China's pharmaceutical sector over the next decade [4]

Group 1 - The company North Sea Kang Cheng-B (01228) announced the grant of a total of 6,372,575 stock options to 30 option grantees under its post-IPO stock option plan [1] - Additionally, the company granted a total of 6,372,575 restricted stock units to 28 grantees under its post-IPO restricted stock unit plan [1] - The exercise price for the granted stock options is set at HKD 2.32 per share [1]

Core Viewpoint - Beihai Kangcheng-B (01228) announced the grant of a total of 6,372,575 stock options and 6,372,575 restricted share units to 30 and 28 recipients respectively, under its post-IPO stock option plan and restricted share unit plan, with an exercise price of HKD 2.32 per share [1] Group 1 - The company granted a total of 6,372,575 stock options to 30 option recipients [1] - The company also granted a total of 6,372,575 restricted share units to 28 recipients [1] - The exercise price for the granted stock options is set at HKD 2.32 per share [1]

Core Viewpoint - Beihai Kangcheng-B (01228.HK) announced the granting of a total of 6,372,575 stock options to 30 option grantees and an equal number of restricted share units to 28 restricted share unit grantees as part of its post-IPO stock option plan and restricted share unit plan [1] Group 1 - The company granted a total of 6,372,575 stock options [1] - The stock options were awarded to 30 option grantees [1] - The company also granted 6,372,575 restricted share units to 28 grantees [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 授出購股權及受限制股份單位 本公告由北海康成製藥有限公司（「本公司」）作出。於2026年1月12日，本公司根據首次公開發售後購 股權計劃向30名購股權承授人授出合共6,372,575份購股權及根據首次公開發售後受限制股份單位計 劃向28名受限制股份單位承授人授出合共6,372,575份受限制股份單位。 授出購股權 於2026年1月12日（交易時段後），本公司根據首次公開發售後購股權計劃向30名購股權承授人授出合 共6,372,575份購股權，惟須待購股權承授人接納後方可作實。 授出購股權的詳情載列如下： 授出日期： 2026年1月12日 購股權承授人數量： 30名（其中24名為非關連購股權承授人，4名為董事購股權承授人及2 名為服務供應商購股權承授人） 授出的購股 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北海康成製藥有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01228 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | ...

Core Insights - The innovative drug sector is experiencing a significant bull market, with the entry threshold for top-performing stocks raised considerably [1] - In 2024, the median stock price increase for the top 10 innovative drug companies was 57.9%, while in 2025, this surged to a median increase of 495.41%, with the highest increase reaching 1824% [2] Group 1: Top Performing Companies - The top-performing stock in 2025 was Beihai Kangcheng, with an astonishing annual increase of 1824%, surprising many in the market [4] - Following Beihai Kangcheng, the second highest was Sanleaf Biotech, which saw an increase of 870%, despite facing significant operational challenges [10] - Yaojie Ankang ranked third with a 773% increase, although its valuation raised concerns due to its limited clinical progress [12] - Heber Pharmaceuticals achieved a 553% increase, driven by its dual-engine model of R&D and business development [16] - Xuan Bamboo Biotech, a newly listed company, experienced a 507% increase, attributed to its new stock status and positive clinical data [20] Group 2: Market Dynamics and Trends - The market has seen a trend of speculative trading, with some companies experiencing price surges not necessarily backed by fundamental improvements [4] - The rise of companies like Heber Pharmaceuticals and Rongchang Biotech illustrates that long-term undervalued firms can achieve significant valuation recovery through continuous R&D and commercialization breakthroughs [4][30] - The innovative drug sector's growth is heavily influenced by liquidity and market sentiment, with many price increases based on speculative expectations rather than solid fundamentals [39] Group 3: Company-Specific Developments - Beihai Kangcheng's stock price recovery was linked to strategic capital injections, resolving its cash flow crisis [7] - Sanleaf Biotech's stock price rebound was primarily driven by its RSV vaccine pipeline, despite facing significant financial pressures [10][11] - Yaojie Ankang's rapid valuation increase raised questions about its sustainability, given its limited clinical advancements [13][14] - Heber Pharmaceuticals' growth was supported by strategic partnerships and a robust technology platform, enhancing investor confidence [18][19] - Rongchang Biotech's stock performance was bolstered by successful product approvals and strategic financing, improving its market outlook [31]

Core Viewpoint - The rare disease innovative drug market is described as a "blue ocean within a blue ocean," with significant unmet clinical needs in China, and the company aims to leverage its dual-core strategy to enhance global innovation and provide hope to more patients [1][2]. Group 1: Company Background and Development - The company, Beihai Kangcheng, has established itself as a global biopharmaceutical firm focused on rare diseases, with three approved products and seven drugs in development [2]. - The founder, Xue Qun, has over ten years of experience in the rare disease sector, identifying significant unmet clinical needs as a fertile ground for entrepreneurship [2]. - Initial challenges included financing difficulties, leading the company to focus on oncology before pivoting to rare diseases after a pivotal policy shift in 2018 [2]. Group 2: Product Portfolio and Clinical Impact - The company's three approved products address multiple clinical gaps, including treatments for Mucopolysaccharidosis Type II and Alagille Syndrome, and the first domestically developed enzyme replacement therapy for Gaucher disease, expected to be approved by May 2025 [3][4]. - The successful launch of the core product, Gorenin, was facilitated by innovative regulatory policies that allowed for segmented production, overcoming high-cost barriers in drug development [4][5]. Group 3: Policy Support and Market Opportunities - Regulatory innovations, such as the segmented production pilot program approved by the National Medical Products Administration, have been crucial in enabling the company to navigate high development costs and enhance production capabilities [5]. - Gorenin's inclusion in the first version of the "Commercial Insurance Innovative Drug Directory" is seen as a significant opportunity to broaden payment channels and enhance the company's innovation drive [6]. Group 4: Strategic Partnerships and Future Plans - The company is entering a 3.0 development phase, implementing a dual-core strategy to solidify its leadership in the domestic rare disease market while expanding internationally [7]. - A strategic partnership with Baiyang Pharmaceutical aims to enhance commercialization efforts and leverage each other's strengths, with Baiyang's extensive sales network significantly exceeding the company's own [7][8]. - The company is actively seeking additional strategic partners in the diagnostic field to create a synergistic ecosystem that combines rare disease diagnostics with genetic sequencing [8].